For Patients With a Positive Sentinel Node in Breast Cancer, Radiotherapy is Comparable to Dissection
the Cancer Therapy Advisor take:
According to a new study published in the journal The Lancet Oncology, dissection and radiotherapy of the axillary lymph node following a positive sentinel node are effective approaches for proving axillary control in patients with T1-2 primary breast cancer without palpable lymphadenopathy.
For the randomized, multicenter, open-label, phase 3 non-inferiority AMAROS study, researchers randomly assigned 4,806 patients to receive axillary lymph node dissection, the current standard of care, or axillary radiotherapy. Patients with positive sentinel lymph nodes were followed for a median of 6.1 years.
Of the 744 patients with a positive sentinel node in the axillary lymph node dissection group, four patients experienced axillary recurrence compared with seven of 681 patients with a positive sentinel node in the axillary radiotherapy group. Results showed a 5-year axillary recurrence rate of 0.43% (95% CI, 0.00 - 0.92) in the dissection group compared with 1.19% (95% CI, 0.31-2.08) in the radiotherapy group.
Axillary lymph node dissection was more often associated with lymphoedema in the ipsilateral arm versus axillary radiotherapy after 1, 3, and 5 years. The findings suggest that axillary radiotherapy provides equivalent regional control with fewer adverse effects versus axillary lymph node dissection.
Radiotherapy of the axillary lymph node following a positive sentinel node effective approach.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed